Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Institute of Biochemistry, University of Crete Medical School, Heraklion, Greece.
FEBS Lett. 2019 Aug;593(15):1879-1900. doi: 10.1002/1873-3468.13494. Epub 2019 Jul 5.
Fibroblast growth factor 23 (FGF23) is mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF23 can exert several endocrine functions, such as inhibiting renal phosphate reabsorption and 1,25-dihydroxyvitamin D3 production. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. Klotho and Fgf23 deficiencies result in pathologies otherwise encountered in age-associated diseases, mainly as a result of hyperphosphataemia-dependent calcification. FGF23 levels are also perturbed in the plasma of patients with several disorders, including kidney or cardiovascular diseases. Here, we review mechanisms controlling FGF23 production and discuss how FGF23 regulation is perturbed in disease.
成纤维细胞生长因子 23（FGF23）主要在骨中产生，分泌后与 FGF 受体和核心受体αKlotho 形成复合物。FGF23 可以发挥多种内分泌功能，例如抑制肾脏对磷酸盐的重吸收和 1,25-二羟维生素 D3 的产生。此外，它对包括中性粒细胞和肝细胞在内的几种细胞类型具有旁分泌活性。Klotho 和 Fgf23 的缺乏会导致与年龄相关疾病中遇到的病理，主要是由于高磷血症依赖性钙化。几种疾病患者的血浆中 FGF23 水平也受到干扰，包括肾脏或心血管疾病。在这里，我们综述了控制 FGF23 产生的机制，并讨论了疾病中 FGF23 调节如何受到干扰。
Zotero 插件